Why the TYK2 Pseudokinase Mechanism Changes the Selectivity Equation

Deucravacitinib (BMS-986165) inhibits TYK2 by binding the regulatory pseudokinase (JH2) domain rather than the catalytic (JH1) domain — an allosteric mechanism that confers selectivity over JAK1, JAK2, and JAK3. This is not a marginal pharmacological distinction: it is the structural basis on which Bristol-Myers Squibb’s entire indication-expansion strategy rests, and it is what differentiates the compound from conventional pan-JAK inhibitors that carry black-box warnings for thrombosis, malignancy, and cardiovascular events.

TYK2 is a member of the Janus kinase (JAK) family and is critical for signalling downstream of type I interferons (IFNs), IL-12, and IL-23. These cytokine pathways are implicated in innate and adaptive immunity across a range of immune-mediated diseases — including psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD). Blocking TYK2 at the JH2 domain stabilises the kinase in an inactive conformation without competing for the ATP-binding site shared across the JAK family, which is the source of off-target JAK1/2/3 activity seen with catalytic inhibitors.

According to research published in peer-reviewed literature, TYK2 inhibition has shown activity across preclinical models of psoriasis, lupus, inflammatory bowel disease, and ankylosing spondylitis, providing a broad mechanistic rationale for the indication-expansion programme. Human genetic data — specifically, TYK2 loss-of-function variants — further support the hypothesis that reducing TYK2 activity is protective rather than harmful in these disease contexts, as noted by researchers examining IL-23 and TYK2 inhibition in mouse models and human genetics.

POETYK PsA: Three Phase 3 Trials and the Biologic-Experienced Frontier

The POETYK PsA programme comprises three phase 3 trials — POETYK PsA-1, POETYK PsA-2, and POETYK PsA-3 — with the third trial specifically designed for biologic-experienced patients, a population that has historically been underserved by oral small-molecule therapies. This three-study architecture reflects Bristol-Myers Squibb’s ambition to position deucravacitinib as an oral alternative across the full PsA treatment continuum, from biologic-naïve patients to those who have failed one or more biologics.

The phase 3 programme followed promising phase 2 results in PsA, as reviewed in published literature. Psoriatic arthritis involves joint inflammation, enthesitis, dactylitis, and skin disease — a multi-domain phenotype that requires a therapy capable of addressing both the articular and cutaneous components. Deucravacitinib’s dual blockade of IL-12 and IL-23 signalling via TYK2 inhibition is mechanistically suited to this multi-domain pathology, since both cytokines drive Th17 and Th1 cell activation relevant to joint and skin inflammation.

The biologic-experienced designation of POETYK PsA-3 is strategically significant. Regulatory agencies including the FDA and the EMA increasingly require evidence of efficacy in biologic-experienced populations before granting broad label claims. A positive readout in POETYK PsA-3 would allow Bristol-Myers Squibb to position deucravacitinib as a later-line oral option — a market segment currently dominated by JAK inhibitors such as upadacitinib and tofacitinib. Deucravacitinib’s selectivity profile could offer a differentiated safety narrative in this context.

SLE and the PAISLEY Signal: What the IFN Data Actually Means

The PAISLEY phase 2 trial evaluated deucravacitinib in adults with systemic lupus erythematosus across five dose arms — 3 mg once daily, 6 mg once daily, 12 mg once daily, 3 mg twice daily, and placebo — over 48 weeks. The primary endpoint, SRI-4 response at week 32, was not met across all arms; however, the 3 mg twice-daily dose showed a higher SRI-4 response rate, and type I IFN gene signature suppression was observed, consistent with TYK2’s established role in IFN signalling.

“Type I IFN gene signature suppression was observed in the PAISLEY trial, consistent with TYK2’s role in IFN signalling — a mechanistic signal that supports continued investigation even where the primary clinical endpoint was not met across all arms.”

The IFN gene signature finding is clinically meaningful because SLE is characterised by a prominent type I IFN signature in the majority of patients — the so-called “interferon high” subpopulation. A pharmacodynamic signal demonstrating IFN pathway suppression provides mechanistic proof-of-concept that deucravacitinib is engaging its target in SLE tissue, even when the composite clinical endpoint (SRI-4) does not reach statistical significance across all dose levels.

Translational pharmacodynamic research in lupus nephritis has further shown that deucravacitinib suppresses type I IFN-driven gene signatures in renal tissue and peripheral blood in models of lupus nephritis, providing mechanistic rationale for its evaluation in this organ manifestation of SLE. This renal data is particularly relevant given that lupus nephritis represents one of the most serious and treatment-resistant manifestations of the disease.

IBD: Dual IL-12/IL-23 Blockade and the Genetic Case for TYK2

TYK2 inhibition is mechanistically rational for inflammatory bowel disease because TYK2 mediates signalling downstream of both IL-12 and IL-23 — the cytokines central to gut inflammation in Crohn’s disease and ulcerative colitis. Deucravacitinib’s allosteric mechanism simultaneously suppresses both IL-12 and IL-23 pathways, providing a dual anti-inflammatory effect that is particularly relevant for gut inflammation, as reviewed in published literature examining IL-23 and TYK2 inhibition in mouse models and human genetics.

The genetic evidence for TYK2 in IBD is unusually strong. Human genetic data showing TYK2 loss-of-function variants associated with IBD risk loci further support the mechanistic hypothesis that reducing TYK2 activity is protective in gut inflammation. This human genetic validation is the same type of evidence that underpinned the development of IL-23 inhibitors — now standard of care in moderate-to-severe Crohn’s disease — and provides a biological anchor for clinical investment in TYK2 inhibition for IBD.

Bristol-Myers Squibb holds patents covering methods of treating inflammatory diseases including Crohn’s disease and ulcerative colitis with deucravacitinib, with dosing regimens and patient selection criteria described. The company’s patent filings — including a 2022 US patent covering TYK2 inhibitor methods in IBD — reflect the breadth of the IP strategy underpinning the IBD expansion programme. According to WIPO patent data, Bristol-Myers Squibb has filed multiple PCT applications covering TYK2 inhibitor compositions and crystalline salt forms for use in IBD and related indications.

Competitive Readouts: Nimbus, Pfizer, and the Next-Generation Challenge

Deucravacitinib’s first-mover advantage in the TYK2 class is real but not permanent. Two well-capitalised competitors are advancing TYK2 inhibitors through clinical development, each with a distinct mechanistic profile and patent estate that will shape the competitive landscape for PsA, SLE, and IBD indications through 2026 and beyond.

Nimbus Therapeutics: NDI-034858 (allosteric, pseudokinase domain)

Nimbus Therapeutics (operating through Nimbus Lakshmi, Inc.) is developing NDI-034858, a selective allosteric TYK2 pseudokinase domain inhibitor — the same mechanistic class as deucravacitinib. In a phase 2 dose-ranging trial in moderate-to-severe plaque psoriasis, NDI-034858 demonstrated significant PASI responses and is being advanced for PsA and other autoimmune indications. Nimbus has filed both allosteric TYK2 inhibitor patents (directed to the JH2 pseudokinase domain) and catalytic-domain JAK/TYK2 inhibitor patents, suggesting a broad IP strategy covering multiple inhibition mechanisms. The head-to-head differentiation from deucravacitinib will depend on phase 3 efficacy and safety data, which are not yet available.

Pfizer: PF-06826647 (catalytic domain, JH1)

Pfizer’s PF-06826647 takes a structurally different approach: it is a catalytic domain (JH1) TYK2 inhibitor, meaning it competes for the ATP-binding site rather than binding the allosteric JH2 domain. Phase 2 data in moderate-to-severe plaque psoriasis demonstrated efficacy; however, the selectivity profile for TYK2 over JAK1, JAK2, and JAK3 at the catalytic domain raises differentiation questions relative to allosteric inhibitors such as deucravacitinib and NDI-034858. Comparative pharmacology research in murine models of psoriasis, arthritis, and lupus found that pseudokinase domain inhibitors showed improved selectivity over JAK1/2/3 compared to JH1 inhibitors — a finding with direct implications for the safety narrative of catalytic-domain compounds in multi-indication development.

The patent landscape reflects this competitive intensity. Bristol-Myers Squibb’s filings cover TYK2 inhibitor compositions, crystalline salt forms, and methods of treating inflammatory diseases including PsA, SLE, Crohn’s disease, and ulcerative colitis. Nimbus holds patents covering both allosteric and catalytic-domain TYK2 inhibitors for the same indication set. Pfizer’s pyrrolopyrimidine-derivative TYK2 inhibitor patents cover psoriasis, PsA, SLE, and IBD. The overlapping claim structures mean that freedom-to-operate analyses will be critical for any entrant seeking to commercialise a second- or third-generation TYK2 inhibitor, according to patent data indexed by PatSnap‘s innovation intelligence platform.